PHASE 5 — REVERSE ENGINEERING & PATHWAY ALIGNMENT | AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation

Phase Code: SCF-CF-AEROVIA201-EBP-P5-0001

Objective: Reverse-engineer the selected SCF Fibonacci stack into disease-specific pathway logic for cystic fibrosis residual airway destruction.

5.1 Reverse-Engineered Disease Loop

CFTR dysfunction
      ↓
Airway surface dehydration
      ↓
Mucus stasis + microbial persistence
      ↓
Neutrophil recruitment
      ↓
Neutrophil elastase excess
      ↓
Elastin / collagen degradation
      ↓
MMP-9 activation + IL-8 amplification
      ↓
Bronchiectasis + ECM collapse
      ↓
Progressive FEV1 decline

5.2 Pathway Alignment Matrix

Disease Node	Therapeutic Component	Intended Correction
Neutrophil elastase excess	AEROVIA-201	Localized elastase modulation
IL-8 / TNF / NF-κB drift	IRD-201H	Cytokine harmonization
ROS overload	NRF-201R	Nrf2-redox support
ECM degradation	ECM-201P	Matrix preservation
CF mucus barrier	DPI-201C + MUC-201P	Pulmonary delivery and mucus penetration
Low lung residence	LRT-201E	Sustained local exposure

5.3 SCF Reverse Engineering Output

SCF Axis	Pathway Translation
Targeted Drug Action	Elastase-centered protease injury loop
Pharmacokinetic Optimization	Inhaled delivery with high lung/plasma ratio
Metabolic Efficiency	Localized exposure to reduce systemic burden
Resistance Prevention	Partial modulation to preserve host defense
Safety Profile	Avoid broad protease or immune suppression

5.4 Molecular Multi-Omics Alignment

Omics Layer	CF Fault Signal	AEROVIA-201 Alignment
Genomics	CFTR-driven epithelial dysfunction	Adjunctive; does not replace CFTR correction
Transcriptomics	IL-8, TNF, NF-κB amplification	Cytokine harmonization module
Proteomics	Neutrophil elastase, MMP-9	Primary target engagement
Metabolomics	ROS, glutathione depletion	Nrf2/redox support
Interactomics	Protease–cytokine feedback loop	Interrupts injury amplification
Microbiomics	Biofilm persistence	Compatible with future anti-biofilm add-on
ECM Layer	Elastin/collagen degradation	Matrix-preservation module

5.5 Mechanistic Alignment Hypothesis

AEROVIA-201 is designed to intervene at the protease-dominant injury node rather than upstream CFTR correction.

Core hypothesis:

Localized elastase modulation will reduce airway structural damage, while cytokine and redox harmonization reduce feedback amplification that sustains progressive CF lung injury.

5.6 Preclinical Pathway Confirmation Panel

Pathway	Confirmation Assay
Elastase activity	Biochemical and CF sputum elastase assay
Protease selectivity	Proteinase 3, cathepsin G, trypsin, chymotrypsin panel
Cytokine drift	IL-8, TNF, IL-6 assay
ECM injury	Elastin degradation, collagen turnover, MMP-9
Redox stress	ROS, glutathione, Nrf2 reporter assay
Barrier preservation	TEER and epithelial integrity assay
Host defense	Bacterial killing preservation assay

5.7 Phase 5 Decision

Pathway alignment result:

AEROVIA-201 aligns strongly with the CF residual lung-destruction axis: neutrophilic inflammation → elastase excess → ECM degradation → bronchiectasis progression.

Decision:

PROCEED TO PHASE 6 — FORMULATION DESIGN & PHARMACOKINETIC MODELING

MASTER REGISTRY INDEX

SCF-CF-AEROVIA201-EBP-P5-0001 — Reverse Engineering & Pathway Alignment

SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator

SCF-CF-S6-0001 — Preclinical Execution & Candidate Validation

SCF-PATH-UT-0001 — SCF Pathophysiology Protocol

SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework

SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow